INCOME TAXES	6 Months Ended
Jun. 30, 2013
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For the three and six months ended June 30, 2013, the effective tax rate (“ETR”) was 25.3% and 25.5%, respectively, compared with 25.9% and 26.7% for the same periods in 2012. The lower ETR was primarily attributable to management's assertion that certain current year foreign earnings and profits are permanently invested abroad. The Company’s gross reserve for uncertain tax positions related to foreign and domestic matters, including penalties and interest, as of June 30, 2013 and December 31, 2012, was $90.3 million and $75.9 million, respectively. The Company believes that it has adequately provided for all uncertain tax positions. It is reasonably possible that new issues may be raised by tax authorities and that these issues may require increases in the balance of uncertain tax positions. Pursuant to the Amended and Restated Tax Matters Agreement dated December 18, 2009, Bristol-Myers Squibb Company (“BMS”), the Company’s former parent, maintains responsibility for all uncertain tax positions which may exist in the pre-initial public offering period or which may exist as a result of the initial public offering transaction. The Company has recorded a receivable from BMS for uncertain tax positions, including penalties and interest, of $8.4 million as of June 30, 2013.

INCOME TAXES

6 Months Ended

Jun. 30, 2013

For the three and six months ended June 30, 2013, the effective tax rate (“ETR”) was 25.3% and 25.5%, respectively, compared with 25.9% and 26.7% for the same periods in 2012. The lower ETR was primarily attributable to management's assertion that certain current year foreign earnings and profits are permanently invested abroad.

The Company’s gross reserve for uncertain tax positions related to foreign and domestic matters, including penalties and interest, as of June 30, 2013 and December 31, 2012, was $90.3 million and $75.9 million, respectively. The Company believes that it has adequately provided for all uncertain tax positions. It is reasonably possible that new issues may be raised by tax authorities and that these issues may require increases in the balance of uncertain tax positions.

Pursuant to the Amended and Restated Tax Matters Agreement dated December 18, 2009, Bristol-Myers Squibb Company (“BMS”), the Company’s former parent, maintains responsibility for all uncertain tax positions which may exist in the pre-initial public offering period or which may exist as a result of the initial public offering transaction. The Company has recorded a receivable from BMS for uncertain tax positions, including penalties and interest, of $8.4 million as of June 30, 2013.